Concepedia

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Kenji Tamura, Junji Tsurutani, Shunji Takahashi, Hiroji Iwata, Ian E. Krop, Charles H. Redfern, Yasuaki Sagara, Toshihiko Doi, Haeseong Park, Rashmi K. Murthy,

The Lancet Oncology · 2019 · 350 citations · 30 references

DOI

Concepts

References

30

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text

, , +14

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016 · 2.1K citations · Full text

, , +11

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

Nadia Howlader, Sean F. Altekruse, Christopher I. Li et al. · JNCI Journal of the National Cancer Institute · 2014 · 1.5K citations · Full text

, , +13

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1.1K citations · Full text

, , +13

Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State

Betsy Kohler, Recinda Sherman, Nadia Howlader et al. · JNCI Journal of the National Cancer Institute · 2015 · 924 citations · Full text

, , +16